Transgene announces promising Phase I preliminary results of its HCV therapeutic vaccine (05 Jun 2008) Preliminary analysis demonstrates a favourable safety profile and shows antiviral activity of TG4040 on chronically infected treatment-naļve patients infected with the HepatitisCVirus (HCV). The trial, conducted in three sites..., NS4 and NS5B) of the hepatitisCvirus. The MVA vector is a highly attenuated... encouraging and indicate that TG4040 is active against hepatitisC", said Philippe...
Santaris Pharma begins human clinical testing of the world's first medicine targeted at a human microRNA (30 May 2008) SPC3649 (LNA-antimiR-122) being developed as a potential new therapy for HepatitisCvirus (HCV) infection by Santaris Pharma as a potential new approach to the treatment for HepatitisC infection... Cvirus replication in liver cells. Keith McCullagh, President & CEO, Santaris... approach to the treatment of HepatitisC and more generally, contribute...
Transgene announces promising phase I preliminary results of its HCV therapeutic vaccine (22 May 2008) Preliminary analysis demonstrates a favourable safety profile and shows antiviral activity of TG4040 on chronically infected treatment-naļve patients infected with the HepatitisCVirus (HCV). The trial, conducted in three sites... encouraging and indicate that TG4040 is active against hepatitisC", said...
OctoPlus presents positive Locteron Phase IIa study results at EASL conference (25 Apr 2008) with the genotype 1 variant of the hepatitisCvirus. The Phase IIa trial was designed... IIa clinical trial of Locteron® for the treatment of chronic hepatitisC (HCV... significant effect of Locteron on the amount of HCV virus particles...
Intercell's therapeutic HepatitisC vaccine meets primary endpoints in Phase II (08 Feb 2008) Data from 50 patients reveal statistically significant viral load reduction and favorable safety profile chronically infected with Genotype 1 of the HepatitisCvirus, which is known... peptidebased therapeutic HepatitisC vaccine (IC41) in an exploratory clinical study targeting treatmentnaļve HepatitisC patients. The vaccine comprises five synthetic...
Inovio Biomedical's DNA Vaccine Delivery Technology Moves Ahead in Clinical Trial for HepatitisC (01 Nov 2007) Inovio initiates 5th DNA vaccine clinical study: hepatitisC vaccine designed to treat chronically infected hepatitisCvirus (HCV) patients... treatment naive patients with chronic hepatitisCvirus infections of genotype... C and its effects on virus replication. "This is the first human study...
Top
